You are here

Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20

HASBROUCK HEIGHTS, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that there will be a Symposium on the Company's lead drug Fexapotide held at the Annual Meeting of the American Urological Association on May 20 in San Francisco. The Symposium is entitled:

“Phase 3 Clinical Studies and Biology of Fexapotide Triflutate Office Injectable for BPH”

and will feature a presentation reviewing therapeutic highlights from the Company’s extensive Phase III trials involving more than 970 patients in the United States. The presentation is chaired by Dr. Ronald Tutrone of Chesapeake Urology Research Associates, Baltimore MD and a panel discussion with panel members including Dr. Mohamed Bidair, San Diego CA; Dr. Ivan Grunberger, New York NY; Dr. Alan Hay, Salem OR; Dr. Susan Kalota, Tucson AZ and Dr. Jeffrey Snyder, Denver CO.

The Annual Meeting of the AUA is the largest urology meeting held annually in the US and brings together over a 4 day period urologists and health care providers, industry and interested parties from across the world with an expected attendance of over 16,000 visitors.

Nymox's fexapotide has been shown to produce long-term improvements in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), a problem that afflicts an estimated 100 million or more men in the world. Fexapotide does not cause the annoying side effects and risks found with available treatments for BPH and has also been shown to lower the occurrence of surgery for BPH.  Fexapotide is also in development for low grade prostate cancer.

For more information please contact or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2017, and its Quarterly Reports.

For Further Information Contact:
Erik Danielsen
Nymox Pharmaceutical Corporation

Wednesday, May 2, 2018 - 09:30